Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Sarcoma × Rosiglitazone × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Thyroid Cancer, Papillary 2 Polycystic Ovary Syndrome 2 Pituitary Neoplasms 2 Neoplasms 2 Diabetes Mellitus, Type 2 2 Adenocarcinoma, Follicular 2 Urinary Bladder Neoplasms 1 Thyroid Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Cancers 1 Sezary Syndrome 1 Sarcoma 1 Prostatic Neoplasms 1 Pancreatic Neoplasms 1 Obesity 1 Mycosis Fungoides 1 Melanoma 1 Lymphoma, T-Cell, Cutaneous 1 Lymphoma, Follicular 1 Liposarcoma 1 Leukoplakia, Oral 1 Head and Neck Neoplasms 1 Central Nervous System Neoplasms 1 Carcinoma, Renal Cell 1 Carcinoma, Hepatocellular 1 Breast Neoplasms 1 Alzheimer Disease 1 Adenocarcinoma Of Esophagus 1

Interventions

Doxorubicin 127 Ifosfamide 76 Radiotherapy 73 Cyclophosphamide 64 Gemcitabine 54 Filgrastim 48 pazopanib 38 pembrolizumab 36 Trabectedin 36 Etoposide 36 Docetaxel 35 Vincristine 34 Cisplatin 30 Nivolumab 29 Magnetic Resonance Spectroscopy 23 Irinotecan 23 Carboplatin 22 Temozolomide 20 Surgical Procedures, Operative 20 Radiation 20 Ipilimumab 20 Mesna 17 Granulocyte Colony-Stimulating Factor 17 Biopsy 17 Bevacizumab 17 Sirolimus 16 Melphalan 16 Blood Specimen Collection 16 eribulin 15 anlotinib 15

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00004180 2023-06-26

Rosiglitazone in Treating Patients With Liposarcoma

Dana-Farber Cancer Institute

Phase 2 Completed

Liposarcoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡